Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutations.
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Melissa L. Johnson(Tennessee Oncology), Chao Huang(The University of Kansas Cancer Center), Sarah Gordon(Virginia Commonwealth University), Susan C. Scott(Johns Hopkins University), M. Ahluwalia(Baptist Hospital of Miami), Danny Nguyen(Harbin Medical University), Nisha Mohindra(Fox Chase Cancer Center), A.I. Spira, Shetal Patel(University of North Carolina at Chapel Hill), Haobin Chen(Washington University in St. Louis), James Stevenson(Cleveland Clinic), Christina S. Baik(University of Washington), Julia K. Rotow(Dana-Farber Cancer Institute), Jyoti D. Patel(Tempus Labs (United States)), David Berz(Los Angeles Clinical Trials), Shannon Matheny(Diamond Materials (United States)), Julio Hajdenberg(Diamond Materials (United States)), Sergey Yurasov(Diamond Materials (United States)), Minal Barve(Mary Crowley Cancer Research Center)
Cited by 1
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459